Last reviewed · How we verify
NCT04278209
Glycogen Metabolism in Children
NA trial testing Breakfast 1 in Healthy in 24 participants. Completed in 30 November 2021.
30 November 2021
Quick facts
| Lead sponsor | Société des Produits Nestlé (SPN) |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 24 |
| Start date | 23 January 2020 |
| Primary completion | 30 November 2021 |
| Estimated completion | 30 November 2021 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Breakfast 1
- Breakfast 2
- Water (WATER) — full drug profile →
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Société des Produits Nestlé (SPN) — full company profile →
Who can join
Adults 8 to 12, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
It is not fully understood in children how much of hepatic and muscle glycogen is used during a night and how they are replenished after a breakfast. This study aims to analyze the glycogen metabolism before and after an overnight sleep as well as after a breakfast in children between 8 and 12 years old.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04278209
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Breakfast 1
Trials testing the same drug.
- NCT05802927 — Diabetes-specific Formula (DSF) in Individuals With Type 2 Diabetes · NA · completed
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Société des Produits Nestlé (SPN) trials
Trials by the same sponsor.
- NCT07312201 — Oral Nutritional Supplementation in Children With Growth Concerns · NA · not yet recruiting
- NCT07378111 — Vegetarian Tube Feed Study · NA · not yet recruiting
- NCT07439718 — The Effects of an Oral Nutritional Intervention on the Small Intestine Microbiome · NA · recruiting
- NCT07341464 — Acceptability and Tolerance Study of Bolus Tube Feed With Food Blends · NA · recruiting
- NCT07127198 — Tolerance and Appetite Reduction of a Nutritional Solution With Intragastric Gelation Properties · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04278209 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Société des Produits Nestlé (SPN)
- Last refreshed: 26 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04278209.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing